A Message from Huge Alerts 
With earnings blowing past expectations and a $9.25 Zacks price target, this biotech company could be ready for BLUE-SKY growth ahead. The biotech arena is home to giants like Merck and Pfizer, but it’s also home to many emerging companies that offer tremendous upside potential. One company in particular has been making waves in headlines recently after reporting a blowout third quarter and getting a nearly $10 price target from Zack’s Small Cap Research! Milestones continue to add up for the company which is on a mission to advance and develop its cutting-edge placental-derived allografts for advanced wound care. This growing company is falling under the radar but could soon hit the spotlight for its role in the diabetes care market. How? The Company harnesses the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company is focused on manufacturing products that change lives, leveraging its proprietary processing method. Not long ago the company was awarded a Q code for one of its products by the Centers for Medicare and Medicaid Services. (CMS). This is a huge milestone and will be effective on January 1st! Zacks Smallcap Research noted: “With the company’s recent announcement of a Q code, we believe rapid growth is set to continue and are raising our valuation level as a result.” Discovery why Zack’s thinks this company is ‘still underpriced’ and why it may see big gains ahead. | 
댓글 없음:
댓글 쓰기